• INDUSTRIES
  • Korea’s BT IndustryRelated Content Download

    Building on active government support and global technology development, growing demand for medical services by the aging population, and activity in the bio-generics field, the South Korean biotechnology (BT) industry has been enjoying continuous growth.

    GROWTH TREND OF BIO INDUSTRY IN KOREA

    MARKET SIZE & NO. OF BIOTECH COMPANIES

    STEM CELL THERAPEUTICS

    13 clinical trials under way regarding DNA therapeutics
    7 global clinical trials under way

    DNA THERAPEUTICS

    Company Disease Ongoing Stage Country
    Lower limb ischemia 2nd phase complete USA

     

     

     

    Diabetic neuropathy 3rd phase approved China

     

     

     

    Lou Gehrig's disease 1/2 phase ongoing USA

     

     

     

    Cardiac infarction 1/2 phase approved USA

     

     

     

     

    Liver cancer 3rd phase approved USA

     

     

     

     

    Degenerative Arthritis 3rd phase approved USA

    The Korean Market, the Preferred Destination for Global Pharmaceutical Companies

    Novartis
    Entered the Korean market in 1984. Has recorded steady and high growth as the world’s number 4 pharmaceutical company. Competitive in pharmaceuticals, vaccines, generic drugs (Sandos), etc.

    MSD
    Entered the Korean market in 1994. Strengthened its organization through the merger of Merck (the head office of MSD Korea) with Schering-Plough in 2009. Developing innovative pharmaceuticals, vaccines, biotherapeutics, etc.

    MERCK
    Entered the Korean market in 1985. Leading the biopharmaceuticals and chemicals industries with its innovative, advanced technology that ensures the highest quality. Merck Group in Korea consists of Merck Ltd., registered in 1989, and Merck Advanced Technologies Ltd., established in 2002.

    SANOFI
    Entered the Korean market in 1991. Growing based on its six key items: emerging markets, vaccines, consumer healthcare, diabetes, drugs and medical supplies, and veterinary drugs.

  • Competitiveness of Seoul’s BT Industry

    Home to the top five general and university hospitals in South Korea, Seoul has become the top clinical trial city in the world (South Korea as a nation is in 10th place) and is fast becoming a major destination for clinical trials.

    CLINICAL TRIALS BY CITY

    COUNTRY PROPORTION COUNTRY PROPORTION
    Seoul 1.04 New York 0.78

     

     

     

     

    Houston 0.78 Madrid 0.77

     

     

     

     

    London 0.64 Barcelona 0.64

     

     

     

     

    Dallas 0.60 Berlin 0.59

     

     

     

     

    Boston 0.58

    GREAT INFRASTRUCTURE FOR CLINICAL TRIAL

    SAMSUNG MEDICAL CENTER
    SEOUL NATIONAL UNIVERSITY HOSPITAL
    KOREA UNIVERSITY MEDICAL CENTER
    SEVERANCE HOSPITAL
    AJOU UNIVERSITY HOSPITAL
    ASAN MEDICAL CENTER
    Highest number of pharmaceutical clinical trials in the world since 2012.(Korea ranked 10th as a country)
    Of 10 Korean government designated "research focused hospitals", 6 are located in Seoul.
  • Korea’s BT IndustryRelated Content Download

    Building on active government support and global technology development, growing demand for medical services by the aging population, and activity in the bio-generics field, the South Korean biotechnology (BT) industry has been enjoying continuous growth.

    GROWTH TREND OF BIO INDUSTRY IN KOREA

    MARKET SIZE & NO. OF BIOTECH COMPANIES

    STEM CELL THERAPEUTICS

    13 clinical trials under way regarding DNA therapeutics
    7 global clinical trials under way

    DNA THERAPEUTICS

    Company Disease Ongoing Stage Country
    Lower limb ischemia 2nd phase complete USA

     

     

     

    Diabetic neuropathy 3rd phase approved China

     

     

     

    Lou Gehrig's disease 1/2 phase ongoing USA

     

     

     

    Cardiac infarction 1/2 phase approved USA

     

     

     

     

    Liver cancer 3rd phase approved USA

     

     

     

     

    Degenerative Arthritis 3rd phase approved USA

    The Korean Market, the Preferred Destination for Global Pharmaceutical Companies

    Novartis
    Entered the Korean market in 1984. Has recorded steady and high growth as the world’s number 4 pharmaceutical company. Competitive in pharmaceuticals, vaccines, generic drugs (Sandos), etc.

    MSD
    Entered the Korean market in 1994. Strengthened its organization through the merger of Merck (the head office of MSD Korea) with Schering-Plough in 2009. Developing innovative pharmaceuticals, vaccines, biotherapeutics, etc.

    MERCK
    Entered the Korean market in 1985. Leading the biopharmaceuticals and chemicals industries with its innovative, advanced technology that ensures the highest quality. Merck Group in Korea consists of Merck Ltd., registered in 1989, and Merck Advanced Technologies Ltd., established in 2002.

    SANOFI
    Entered the Korean market in 1991. Growing based on its six key items: emerging markets, vaccines, consumer healthcare, diabetes, drugs and medical supplies, and veterinary drugs.

  • Competitiveness of Seoul’s BT Industry

    Home to the top five general and university hospitals in South Korea, Seoul has become the top clinical trial city in the world (South Korea as a nation is in 10th

    CLINICAL TRIALS BY CITY

    COUNTRY PROPORTION COUNTRY PROPORTION
    Seoul 1.04 New York 0.78

     

     

     

     

    Houston 0.78 Madrid 0.77

     

     

     

     

    London 0.64 Barcelona 0.64

     

     

     

     

    Dallas 0.60 Berlin 0.59

     

     

     

     

    Boston 0.58

    GREAT INFRASTRUCTURE FOR CLINICAL TRIAL

    SAMSUNG MEDICAL CENTER
    SEOUL NATIONAL UNIVERSITY HOSPITAL
    KOREA UNIVERSITY MEDICAL CENTER
    SEVERANCE HOSPITAL
    AJOU UNIVERSITY HOSPITAL
    ASAN MEDICAL CENTER
    Highest number of pharmaceutical clinical trials in the world since 2012.(Korea ranked 10th as a country)
    Of 10 Korean government designated "research focused hospitals", 6 are located in Seoul.

Copyright © 2017 Invest SEOUL Co. Ltd ALL RIGHTS RESERVED.